Pharmaceutical

UCB to divest China neurology and allergy business for $680m

UCB has entered a divestment agreement in China to sell its mature neurology and allergy business to CBC Group and Mubadala for $680m.

Aug 27, 2024 - 04:00
UCB to divest China neurology and allergy business for $680m
UCB has entered a divestment agreement in China to sell its mature neurology and allergy business to CBC Group and Mubadala for $680m.
Read the original article

Tags:

Previous Article

Key discovery by Duke-NUS advances fight to reduce breast cancer recurrence

Next Article

MSD snags European approval for pulmonary arterial hypertension therapy

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

How to take advantage of the connected health opportunity in your next drug launch

How to take advantage of the connected health opportuni...

May 23, 2024

BNT-325 by Duality Biologics (Shanghai) for Metastatic ...

Jul 6, 2024

STAT+: WTO appears close to rejecting a proposed waiver on patents for Covid diagnostics and therapies

STAT+: WTO appears close to rejecting a proposed waiver...

Feb 1, 2024